Pfizer expects $54 billion in 2022 sales on Covid vaccine and treatment pill

Pfizer expects to sell $32 billion of its Covid-19 shots and $22 billion of its antiviral coronavirus treatment pill Paxlovid.
But the drugmaker posted mixed fourth-quarter results, beating on earnings but missing on revenue.
Pfizer forecasts $98 billion to $102 billion in sales for 2022, and adjusted earnings per share of $6.35 to $6.55.
On an unadjusted basis, fourth-quarter profit soared more than fourfold to $3.39 billion.